Disclosures: Hiroshi Horie: Nothing to Disclose, Ken Fukumitsu: Nothing to Disclose, Kentaro Iwaki: Nothing to Disclose, Fumiaki Munekage: Nothing to Disclose, Kenta Makino: Nothing to Disclose, Katsuhiro Tomofuji: Nothing to Disclose, Hidenobu Kojima: Nothing to Disclose, Elena Uebayashi: Nothing to Disclose, Satoshi Ogiso: Nothing to Disclose, Takamichi Ishii: Nothing to Disclose, Etsuro Hatano: Nothing to Disclose 2076 THE PPAR-DELTA AGONIST SELADELPAR NORMALIZES PRIMARY BILIARY CHOLANGITIS-LIKE FEATURES IN HUMAN CHOLANGIOCYTES AND REDUCES PATHOLOGICAL IMMUNE ACTIVATION Francisco Caballero-Camino 1 Irune Lasa 2 Ainhoa Lapitz 1 Xia Wu 3 Pedro Rodrigues 1 Noelia Pastor-Toyos 1 Laura Izquierdo-Sanchez 1 Jiangao Song 3 Edward Cable 3 Jeffrey Johnson 3 Yun-Jung Choi 3 Charles McWherter 3 Jesus Banales 1 , 1 Biogipuzkoa Health Research Institute, Donostia University Hospital,University of the Basque Country, 2 Biogipuzkoa Health Research Institute,Donostia University Hospital,University of the Basque Country, 3 CymaBay Therapeutics Background: Primary biliary cholangitis (PBC) is a chronic cholestatic and immune-mediated liver disease characterized by the progressive impairment and destruction of bile duct epithelial cells (i.e., cholangiocytes)
However, results can vary
These include supplementing with select herbs or minerals to promote the production of GLP-1 in addition to a healthy diet and exercise routine
Ozempic EPAR Product Information
